peptide therapy bpc 157 BPC-157 Beverly Hills Peptide Therapy in Austin, TX

All laboratory analyses were performed in blinded fashion at the Biomarker Laboratory of the Department of Internal Medicine II-Cardiology, Ulm University Medical Center

The Phase 2 trial documented these side effects across all dose groups, and the data tells a clear story: most symptoms are gastrointestinal, most are mild to moderate, and most improve as the body adapts

In Draft Labeling Text (pp

Czechia Greater than 99.8 % purity confirmed by COA Assay content verified at 55.1 mg Endotoxin level below 0.001 EU/mg No detectable heavy metals or microbial contamination NNMT-related research compound for controlled laboratory studies For research use only not for human or veterinary use For laboratory research only